¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"gradient induced phase shift effect"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • halo effect
    ´Þ¹«¸®È¿°ú
  • isotopic effect
    µ¿À§¿ø¼ÒÈ¿°ú
  • inflow effect
    À¯ÀÔÈ¿°ú
  • inotropic effect
    ¼öÃàÃËÁøÈ¿°ú
  • late effect
    ¸¸±âÈ¿°ú
  • latitude effect
    À§µµÈ¿°ú
  • masking effect
    ÀºÆóÈ¿°ú
  • mass effect
    µ¢ÀÌÈ¿°ú, Á¾±«È¿°ú
  • mesomeric effect
    °ø¸íÈ¿°ú
  • magnetic field effect
    ÀÚÀåÈ¿°ú
  • no-observed-effect level
    ¹«°üÂûÈ¿°ú¼öÁØ
  • on-off effect
    °³½ÃÁ¾·áÈ¿°ú
  • osmolality effect
    ¸ô¶ö»ïÅõ¾ÐÈ¿°ú
  • overkill effect
    °úÀ×Ä¡»çÈ¿°ú
  • photochemical effect
    ±¤È­ÇÐÈ¿°ú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • biologic effect
    »ý¹°ÇÐÀûÈ¿°ú
  • blow back effect
    µÞ¹Ù¶÷È¿°ú, ÈÄdzȿ°ú
  • bridle effect
    °í»ßÈ¿°ú, Á¦¾îÈ¿°ú
  • carrier effect
    ¿î¹Ýüȿ°ú
  • carry-over effect
    ÀÜÈ¿
  • cavitation effect
    °øµ¿È¿°ú
  • ceiling effect
    ÃÖ°íÈ¿°ú
  • clasp-knife effect
    Á¢´ÂĮȿ°ú
  • cohort effect
    ÄÚȣƮȿ°ú
  • combined effect
    º´¿ëÈ¿°ú
  • concentration effect
    ³óµµÈ¿°ú
  • cumulative effect
    ´©ÀûÈ¿°ú, ÃàÀûÈ¿°ú
  • curative effect
    Ä¡·áÈ¿°ú
  • cytopathic effect
    ¼¼Æ÷º´º¯È¿°ú
  • delayed effect
    Áö¿¬È¿°ú
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • Go phase
    Go±â
  • accelerated death phase
    °¡¼Ó»ç¸ê±â(˧ËÛË×ËÎË»).
  • acceleration phase
    ÃËÁø±â, °¡¼Ó±â(Ê¥áÜÑ¢).
  • acute phase protein
    ±Þ¼ºº´±â´Ü¹éÁú
  • acute phase reactant
    ±Þ¼º±â ÀÛ¿ë¹°Áú
  • acute phase reaction
    ±Þ¼º±â¹ÝÀÀ(¡­Ñ¢Úãëë)
  • acute phase reactive protein
    ±Þ¼º±â ¹ÝÀÀ¼º ´Ü¹é.
  • acute phase serum
    ±Þ¼ºº´±âÇ÷û
  • acute phase substances
    ±Þ¼º±â ¹°Áú(ÐáàõÑ¢Úªòõ).
  • advanced sleep phase syndrome
    ÀüÁø¼º ¼ö¸éÀ§»ó ÁõÈıº
  • anal-sadistic phase
    Ç×¹®-°¡ÇÐ(½Ã)±â
  • arterial phase
    µ¿¸Æ±â
  • full erection phase
    ¿ÏÀü¹ß±â±â
  • g0 phase
    Á¤Áö±â G0±â
  • g1 phase
    ÇÕ¼ºÀü±â G1±â
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • induced mutation
    À¯¹ßµ¹¿¬º¯ÀÌ
  • induced ovulation
    À¯µµ¹è¶õ
  • induced phagocytosis
    À¯µµÅ½½Ä
  • induced phagocytosis
    À¯¹ß½ÄÀÛ¿ë.
  • induced polarization
    À¯¹ß(µµ)ºÐ±Ø.
  • induced psychosis
    °¨ÀÀ¼º Á¤½Åº´.
  • induced reaction
    À¯¹ß(µµ)¹ÝÀÀ.
  • induced shock
    À¯µµ(ë¯Óô)¼ï.
  • induced sleep
    À¯µµ¼ö¸é(ë¯Óôâ²Øù)
  • induced sleep
    À¯µµ¼ö¸é(¡­â²Øù).
  • induced spindle burst
    À¯¹ß¹æÃßµ¹¹ßÆÄ.
  • induced symptom
    À¯¹ßÁõ»ó.
  • induced variation
    À¯µµº¯ÀÌ.
  • insulin-induced hypoglycemia
    Àν¶¸°À¯µµÀúÇ÷´ç(Áõ)
  • jaundice, drug-induced
    ¾à¹°À¯¹ß¼ºÈ²´Þ(å·Úªë¯Û¡àõüÜÓ¸)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • propinquit effect
    ±ÙÁ¢È¿°ú(ÐÎïÈüùÍý)
  • proximity effect
    ±ÙÁ¢È¿°ú(ÐÎïÈüùÍý)
  • Raman effect
    ¶ó¸¸ È¿°ú(üùÍý)
  • relaxation effect
    ÀÌ¿Ï È¿°ú(ì¬èÐüùÍý)
  • secondary charge effect
    ÀÌÂ÷ ÇÏÀüÈ¿°ú(ì£ó­ùÃï³üùÍý)
  • secondary isotope effect
    ÀÌÂ÷ µ¿À§¿ø¼ÒÈ¿°ú(ì£ó­ÔÒêÈêªáÈüùÍý)
  • sparing effect
    ¿¹ºñÈ¿°ú(çãÝáüùÍý)
  • spreading position effect
    ÆÛÁü À§Ä¡ È¿°ú(êÈöÇüùÍý)
  • Stark effect
    ½ºÅ¸Å© È¿°ú(üùÍý)
  • thyrotoxic effect
    °©»ó¼±Áßµ¶ È¿°ú (Ë£ßÒàÍñéÔ¸üùÍý)
  • time factor effect
    ½Ã°£ÀÎÀÚ È¿°ú (ãÁÊàì×í­üùÍý)
  • trans effect
    Æ®¶õ½º È¿°ú(üùÍý)
  • Tyndall effect
    ƾ´Þ È¿°ú(üùÍý)
  • wall effect
    º®(Ûú)È¿°ú(üùÍý)
  • Warbug effect
    ¹Ù¸£ºÎ¸£Å© È¿°ú(üùÍý)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • susceptibility gradient
    ÀÚÈ­À²°æ»ç
  • volume gradient echo technique
    ¿ëÀû°æ»ç¿¡ÄÚ±â¹ý
  • X gradient
    XÃà °æ»ç
  • Y gradient
    YÃà °æ»ç
  • Z gradient
    ZÃà°æ»ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 11
EAE Early Asthmatic Effect
LAE   1) Late Asthmatic Effect
  2) Left Atrial Enlargement
SE Side Effect
AE above-elbow [amputation]; acrodermatitis enteropathica; activation energy; adult erythrocyte; advers...
AEF allogenic effect factor; amyloid enhancing factor; aorto-enteric fistula
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 11
LOEL Lowest Observed Effect Level
LOEC Lowest observed effect concentrations
ME McCollough Effect
NOAEL No Observable Adverse Effect Level
NOEL No Observable Effect Level
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • efferent effect
    ¿ø½É È¿°ú
  • entry slice effect
    À¯ÀÔ ´Ü¸é È¿°ú
  • first pass effect
    ÀÏÂ÷ Åë°ú È¿°ú
  • focus effect
    ÃÐÁ¡ È¿°ú
  • harmful effect
    À§ÇØ ÀÛ¿ë
    À§ÇèÇÑ ÀçÇØ. Á¶Á÷À̳ª »ý¸íü¿¡ ÇØ·Î¿î ¿µÇâÀ» ³¢Ä¡´Â ÀÛ¿ë.
  • heel effect
    Èú È¿°ú
    ¾ç±Ø °æ»ç °¢µµ¿¡ µû¸¥ È¿°ú.
  • indirect effect
    °£Á¢ È¿°ú
  • isotopic effect
    µ¿À§ ¿ø¼Ò È¿°ú
  • lethal effect
    Ä¡»ç È¿°ú
  • longitudinal effect
    Á¾ È¿°ú, Á¾Àû È¿°ú
  • misregistration effect
    ¿Àµî·Ï È¿°ú
  • modulating effect
    Á¶Àý È¿°ú
  • muscle effect
    ±ÙÀ° È¿°ú
  • myocardium,aging effect
    ³ëÈ­ Çö»ó
  • Nagler effect
    ³ª±Û·¯ È¿°ú
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
Purkinje effect <ophthalmology> In the light-adapted eye, the region of maximal brightness is in the yellow; in the dark-adapted eye, the region of maximal brightness is in the green.
Synonym: Purkinje effect, Purkinje shift.
(05 Mar 2000)
hydrophobic effect <chemistry> The tendency for the nonpolar portions of a group of lipid molecules to clump together with one another and exclude water and other polar molecules. The polar portions of the lipid molecules end up facing out. The hydrophobic effect is primarily responsible for the construction of lipid bilayers.
(09 Oct 1997)
side effect <pharmacology> A consequence other than the one for which an agent or measure is used, as the adverse effects produced by a drug, especially on a tissue or organ system other than the one sought to be benefited by its administration.
For example: hair loss may be a side effect of chemotherapy, fatigue may be a side effect of radiation therapy.
(14 Oct 1997)
hyperchromic effect An increase in absorptivity (or extinction) at a particular wavelength of light by a solution or substance due to structural changes in a molecule.
(05 Mar 2000)
sigma effect The decrease in apparent viscosity that occurs when a suspension, such as blood, is made to flow through a tube of smaller diameter; observed in tubes less than about 0.3 mm in diameter.
Synonym: sigma effect.
(05 Mar 2000)
hypochromic effect A phenomenon in which an individual molecule, containing several chromophores, has a certain absorptivity (or optical density) at a given wavelength that is less than the sum of the optical densities of the individual chromophores (at that same wavelength).
(05 Mar 2000)
Somogyi effect In diabetes, a rebound phenomenon of reactive hyperglycaemia in response to a preceding period of relative hypoglycaemia that has increased secretion of hyperglycaemic agents (epinephrine, norepinephrine, glucagon, cortisol, and growth hormone); described in diabetic patients given too much insulin who developed unrecognised nocturnal hypoglycaemia that made them hyperglycaemic (suggesting insufficient insulin) when tested the next morning.
(05 Mar 2000)
stark effect <radiobiology> The effect an electric field has on the spectral lines emitted from excited atoms.
The effect may arise from externally-applied electric fields, from internal fields due to the presence of neighboring ions or atoms (pressure), or from the electric field associated with the Lorentz (v cross B) force (motional stark effect). Spectroscopic measurements of plasmas using the pressure-based and motional Stark effects are useful for diagnostic purposes.
(09 Oct 1997)
Staub-Traugott effect In normal persons, a drop in blood glucose which follows a second oral dose of glucose given 30 minutes or so after the first.
(05 Mar 2000)
Stiles-Crawford effect Light that enters through the centre of the pupil produces a greater visual effect than light that enters obliquely.
(05 Mar 2000)
no-observed-adverse-effect level The highest dosage administered that does not produce toxic effects. The noael will depend on how closely dosages are spaced (lowest-observed-adverse-effect level and no-observed-effect level) and the number of animals examined. The ultimate objective is usually to determine not the "safe" dosage in laboratory animals but the "safe" dosage for humans. Therefore, the extrapolation most often required of toxicologists is from high-dosage studies in laboratory animals to low doses in humans. (casarett and doull's toxicology: the basic science of poisons, 4th ed)
(12 Dec 1998)
nuclear Overhauser effect <enzyme> An enzyme seen in nuclear magnetic resonance in which there is a through-space nearest neighbor interaction.
(05 Mar 2000)
synergistic effect The doctrine or theory, attributed to Melanchthon, that in the regeneration of a human soul there is a cooperation, or joint agency, on the part both of God and of man.
See: Synergetic.
Source: Websters Dictionary
(01 Mar 1998)
doppler effect <radiobiology> Variation in the frequency of a wave (as measured by an observer) due to relative motion between the observer and the source of the wave. (The observed frequency increases if the source is moving towards the observer and vice versa.) The equation can be found in most optics texts and many introductory physics texts.
(09 Oct 1997)
dosage effect The alteration of a phenotype by an increased dosage, or amount, of the product of the gene.
(09 Oct 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 11
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 11
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 11
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 11
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 11
ÅëÇÕ°Ë»ö ¿Ï·á